从不良预后到精确的希望：针对braf突变的转移性结直肠癌的临床试验

IF 11.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-09-12 DOI:10.1016/j.medj.2025.100811

Hironaga Satake, Hideaki Bando, Shin Kobayashi, Takayuki Yoshino

引用次数: 0

摘要

BRAF v600e突变型转移性结直肠癌是一种罕见的预后不良亚型，历来治疗选择有限。不断发展的方法，包括靶向组合和基于免疫治疗的研究性策略，提供了改善结果的潜力。我们强调不断发展的治疗前景和新兴的策略，为这种分子独特的亚型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

From poor prognosis to precision promise: Clinical trials targeting BRAF-mutant metastatic colorectal cancer.

BRAF V600E-mutant metastatic colorectal cancer, a rare subtype with poor prognosis, has historically carried limited treatment options. Evolving approaches, including targeted combinations and investigational immunotherapy-based strategies, offer potential to improve outcomes. We highlight the evolving treatment landscape and emerging strategies for this molecularly distinct subtype.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.